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Introduction
It’s crucial to observe the changes in disease activity in JIA
in order to investigate reliably the effects of the new treat-
ments and to optimize their use. Several tools for outcome
measurements have been developed. Juvenile Arthritis
Disease Activity Score (JADAS) is an independent measure
of the treatment response and enables the comparison
between cohorts. However, the use of ESR restricts the
feasibility of JADAS. That’s why a JADAS index excluding
ESR has been tested (JADAS3). In order to simplify
the interpretation of the JADAS score, efforts have
been made to define cut-off values of JADAS for low
and high diease activity. Cut-off values of JADAS for
disease activity levels, as defined by ACR, have not
been developed. Neither have any cut-off values for
JADAS3 been defined.
Objectives
Our aim was to define the cut-off values for low, mod-
erate, and high disease activity of JADAS-10 and
JADAS3-10.
Methods
In a multicenter study consisting 20% of all patients with
juvenile idiopathic arthritis in Finland (n=514), data on
last registered visits and on visits fulfilling the criteria for
high disease activity were obtained. JADAS-10 and
JADAS3-10 were calculated, and the cut-off values of both
of these scores were determined by 3 different ROC-based
statistical methods.
Results
Of 514 patients included, 65.5% were females and 54.1%
had polyarticular disease. The most suitable method for
determining cut-off values was the 90% specificity index.
The cut-off value for low disease activity was 0.2 for
both JADAS-10 and JADAS3-10 in both oligoarticular
and polyarticular disease. In oligoarticular disease, the
cut-off value for moderate disease activity was 2.8 for
JADAS-10 and 2.4 for JADAS3-10 and in polyarticular
disease 4.1 for both JADAS-10 and JADAS3-10. In
patients with polyarticular disease, the cut-off value for
high disease activity of JADAS-10 and JADAS3-10 was
16.3 and 16.0.
Conclusion
Cut-off values for low, moderate and high disease activity
were defined. In clinical setting, research and quality
control, JADAS3-10 can be used instead of JADAS-10. In
the future, uniform, clinical disease activity levels need to
be set. Valid and robust cut-off values of disease activity
levels can guide both a clinician and a researcher, and
equip in benchmarking.
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